Olema Pharmaceuticals Inc (OQ:OLMA)

Business Focus: Biotechnology & Medical Research

Mar 11, 2024 04:03 pm ET
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
Mar 06, 2024 07:03 am ET
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that...
Mar 04, 2024 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Feb 06, 2024 07:01 am ET
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will...
Feb 02, 2024 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Jan 08, 2024 08:12 am ET
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced the selection...
Jan 02, 2024 04:01 pm ET
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
Dec 05, 2023 12:27 pm ET
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced interim...
Dec 04, 2023 04:29 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Nov 28, 2023 05:10 pm ET
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will...
Nov 07, 2023 04:02 pm ET
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
Nov 02, 2023 04:32 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Nov 01, 2023 04:27 pm ET
Olema Oncology to Participate in Upcoming Investor Conferences in November
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Oct 22, 2023 02:55 am ET
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today...
Oct 17, 2023 07:01 am ET
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the...
Oct 16, 2023 07:02 am ET
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an oral...
Oct 12, 2023 07:01 am ET
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced new...
Oct 10, 2023 07:00 am ET
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an amendment...
Oct 03, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Sep 20, 2023 07:29 am ET
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster...
Sep 06, 2023 04:30 pm ET
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Sep 05, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Sep 05, 2023 07:30 am ET
Olema Oncology Announces Combined Financing for Up to $180 Million
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, announced today that it has...
Aug 08, 2023 04:03 pm ET
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
Aug 02, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Aug 01, 2023 08:00 am ET
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
Jul 05, 2023 07:30 am ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Jun 02, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
May 30, 2023 04:30 pm ET
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
May 11, 2023 08:43 am ET
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA) today announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and...
May 09, 2023 04:01 pm ET
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
May 08, 2023 07:06 am ET
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster...
May 02, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Apr 13, 2023 04:30 pm ET
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean...
Apr 04, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Mar 09, 2023 04:00 pm ET
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
Mar 02, 2023 05:00 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Mar 02, 2023 04:05 pm ET
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean...
Feb 21, 2023 04:30 pm ET
Olema Oncology to Participate at Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Feb 02, 2023 06:00 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Jan 04, 2023 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the...
Jan 03, 2023 07:00 am ET
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on...
Dec 07, 2022 03:37 pm ET
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA) today announced results from a Phase 1b dose escalation clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and...
Dec 02, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Nov 21, 2022 09:16 am ET
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the...
Nov 08, 2022 04:30 pm ET
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported third quarter...
Nov 02, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Nov 01, 2022 08:00 am ET
Olema Oncology to Present at Upcoming Investor Conferences in November
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Oct 26, 2022 03:00 am ET
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology” or the “Company”, Nasdaq: OLMA) today announced preliminary clinical results from a Phase 1/2 clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and...
Oct 12, 2022 07:01 am ET
Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the Company will present updated clinical results from the OP-1250-001 study at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Oct 04, 2022 04:29 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Sep 06, 2022 04:30 pm ET
Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Sep 01, 2022 05:01 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Aug 09, 2022 04:35 pm ET
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported second...
Aug 09, 2022 04:30 pm ET
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the...
Aug 04, 2022 04:30 pm ET
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
Aug 03, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Jul 21, 2022 07:30 am ET
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the Company's novel, oral complete estrogen receptor (ER)...
Jul 05, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Jun 09, 2022 07:35 am ET
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced clinical development progress for OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the...
Jun 09, 2022 07:30 am ET
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule...
Jun 02, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
May 24, 2022 04:30 pm ET
Olema Oncology to Present at Jefferies Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
May 09, 2022 04:30 pm ET
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported first quarter...
May 03, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Apr 18, 2022 04:30 pm ET
Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Apr 04, 2022 07:30 am ET
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in...
Mar 08, 2022 04:35 pm ET
Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced plans to...
Feb 28, 2022 04:30 pm ET
Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
Feb 22, 2022 07:30 am ET
Olema Oncology to Present at Cowen 42nd Annual Health Care Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care...
Feb 03, 2022 05:00 pm ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today...
Jan 31, 2022 07:30 am ET
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced the...
Jan 04, 2022 07:30 am ET
Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the 40th Annual J.P. Morgan Healthcare...
Nov 30, 2021 07:00 am ET
Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the first...
Nov 29, 2021 04:27 pm ET
Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, has been alerted to falsified...
Nov 22, 2021 07:30 am ET
Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two poster...
Nov 10, 2021 04:05 pm ET
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today provided an update on...
Nov 09, 2021 07:30 am ET
Olema Oncology to Present at Two Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that...
Sep 30, 2021 05:00 pm ET
Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster...
Sep 09, 2021 07:30 am ET
Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster...
Aug 30, 2021 04:05 pm ET
Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
Aug 10, 2021 04:05 pm ET
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today provided an update on...
Jul 28, 2021 04:05 pm ET
Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
May 18, 2021 04:05 pm ET
Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
May 11, 2021 04:05 pm ET
Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today provided an update on...
Apr 07, 2021 07:30 am ET
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P....
Apr 06, 2021 07:30 am ET
Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the...
Mar 17, 2021 04:05 pm ET
Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial...
Mar 10, 2021 04:45 pm ET
Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on...
Feb 23, 2021 07:00 am ET
Olema Oncology to Participate at Upcoming Virtual Investor Conferences
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will...
Dec 17, 2020 07:00 am ET
Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P....
Dec 07, 2020 07:39 am ET
Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to...
Nov 23, 2020 04:01 pm ET
Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closing of its...
Nov 18, 2020 08:09 pm ET
Olema Oncology Announces Pricing of Initial Public Offering
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.